Kim YH - Search Results

1

Re-thinking about prophylactic cranial irradiation for small cell lung cancer in the MRI era.

Ouchi A, Kim YH, Iwatsubo S, Nishimura Y, Funada Y. Ouchi A, et al. Among authors: kim yh. J Thorac Dis. 2021 Aug;13(8):5115-5116. doi: 10.21037/jtd-21-870. J Thorac Dis. 2021. PMID: 34527350 Free PMC article. No abstract available.

2

Dual inhibition of BRAF and MEK in BRAF-mutated metastatic non-small cell lung cancer.

Kim YH. Kim YH. J Thorac Dis. 2016 Sep;8(9):2369-2371. doi: 10.21037/jtd.2016.09.16. J Thorac Dis. 2016. PMID: 27746978 Free PMC article. No abstract available.

3

Management and Outcomes of Newly Diagnosed Non-Small Cell Lung Cancer Patients with Brain Metastases: A Real-World Study in Japan.

Yoshida H, Kim YH, Iwatsubo S, Sakaguchi C, Sakamori Y, Nagai H, Ozasa H, Mio T, Hirai T. Yoshida H, et al. Among authors: kim yh. Oncology. 2020;98(7):460-467. doi: 10.1159/000506368. Epub 2020 Mar 27. Oncology. 2020. PMID: 32222702

4

How should we manage non-small-cell lung cancer "not-otherwise-specified"?

Kim YH, Nishimura Y, Funada Y. Kim YH, et al. Med Oncol. 2021 Jun 12;38(7):82. doi: 10.1007/s12032-021-01531-9. Med Oncol. 2021. PMID: 34117925 No abstract available.

5

The Role of Dual Inhibition of EGFR and Vascular Endothelial Growth Factor (Receptor) in the Treatment of NSCLC With EGFR Mutation.

Yamaoka T, Kim YH, Iwatsubo S, Nishimura Y, Funada Y. Yamaoka T, et al. Among authors: kim yh. J Thorac Oncol. 2021 Sep;16(9):e71-e72. doi: 10.1016/j.jtho.2021.06.003. J Thorac Oncol. 2021. PMID: 34426001 Free article. No abstract available.

6

Exacerbation of nontuberculous mycobacterial pulmonary disease in a patient with advanced non-small-cell lung cancer during treatment with PD-1 inhibitor and chemotherapy.

Okamoto M, Kim YH, Ouchi A, Yamaoka T, Iwamoto N, Iwatsubo S, Matsumura K, Nakamura M, Kin Y, Shiina Y, Funada Y. Okamoto M, et al. Among authors: kim yh. Respir Med Case Rep. 2021 Oct 21;34:101529. doi: 10.1016/j.rmcr.2021.101529. eCollection 2021. Respir Med Case Rep. 2021. PMID: 34745866 Free PMC article.

7

Role of Postoperative Radiotherapy in Patients With Completely Resected pIIIA-N2 Non-Small Cell Lung Cancer.

Yamasaki N, Kim YH, Iwatsubo S, Nishimura Y, Funada Y. Yamasaki N, et al. Among authors: kim yh. Clin Lung Cancer. 2022 May;23(3):e171-e172. doi: 10.1016/j.cllc.2021.09.008. Epub 2021 Oct 2. Clin Lung Cancer. 2022. PMID: 34756510 No abstract available.

8

Is there a role for sequential afatinib and osimertinib in patients with EGFR mutation?

Iwamoto N, Kim YH, Iwatsubo S, Nishimura Y, Funada Y. Iwamoto N, et al. Among authors: kim yh. J Thorac Dis. 2022 Jan;14(1):207-209. doi: 10.21037/jtd-21-1700. J Thorac Dis. 2022. PMID: 35242383 Free PMC article. No abstract available.

9

Pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small cell lung cancer and chronic renal failure who are undergoing hemodialysis.

Togashi Y, Masago K, Fukudo M, Terada T, Ikemi Y, Kim YH, Fujita S, Irisa K, Sakamori Y, Mio T, Inui K, Mishima M. Togashi Y, et al. Among authors: kim yh. J Thorac Oncol. 2010 May;5(5):601-5. doi: 10.1097/JTO.0b013e3181d32287. J Thorac Oncol. 2010. PMID: 20234322 Free article.

10

Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer.

Togashi Y, Masago K, Fukudo M, Terada T, Fujita S, Irisa K, Sakamori Y, Kim YH, Mio T, Inui K, Mishima M. Togashi Y, et al. Among authors: kim yh. J Thorac Oncol. 2010 Jul;5(7):950-5. doi: 10.1097/JTO.0b013e3181e2138b. J Thorac Oncol. 2010. PMID: 20479691 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

12,834 results

Search Page

Filters